AtriCure Inc (Nasdaq:ATRC) on Tuesday reported the completion of the acquisition of SentreHEART Inc for an undisclosed amount.
Based in Redwood City, California, SentreHEART is a privately-owned medical device company committed to clinical evidence development and is currently sponsoring the FDA-approved prospective, multi-centre, randomized controlled trial (aMAZE Trial).
Founded in 2005, SentreHEART has developed innovative technology for remote delivery of suture for closure of anatomic structures including the left atrial appendage (LAA).
According to AtriCure Inc, it provides innovative technologies for the treatment of Afib and related conditions. The electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications.
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Emmaus Life Sciences' Endari label enhancements receive US FDA approval
Accord Healthcare introduces Dehydrated Alcohol Injection for cardiovascular indications
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Sanofi receives FDA orphan drug designation for riliprubart in transplant rejection
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Breckenridge Pharmaceutical's generic for Ablysinol granted final FDA approval
Hemab Therapeutics presents bleeding disorder clinical and preclinical data at ISTH 2025 Congress